

## Enalaprilat Dihydrate

### Chemical Properties


CAS No. : 84680-54-6

Formula: C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>·2H<sub>2</sub>O

Molecular Weight: 348.4

Storage: Store at low temperature, Keep away from moisture  
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



### Biological Description

Description	Enalaprilat Dihydrate (MK-422 Dihydrate) (IC <sub>50</sub> =1.94 nM) is a potent angiotensin-converting enzyme (ACE) inhibitor.
Targets(IC <sub>50</sub> )	RAAS, Autophagy, Angiotensin-converting Enzyme (ACE)
In vitro	Enalaprilat has high affinity for human endothelial ACE with IC <sub>50</sub> of 1.94 nM in vitro binding assay by displacing a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments. [1] Enalaprilat has the strong inhibitory effect on Aβ <sub>42</sub> -to-Aβ <sub>40</sub> -converting activity found in the N-domain of ACE, exhibiting a 10-fold lower IC <sub>50</sub> (0.003~0.01 μM) than captopril (0.03~0.1 μM). [2] Enalaprilat (100 nM) blocks protein kinase C epsilon by directly activating bradykinin B1 receptor at the canonical Zn <sup>2+</sup> binding site, leading to prolonged nitric oxide (NO) production in cytokine-treated human lung microvascular endothelial cells. [3] Enalaprilat attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with IC <sub>50</sub> of 90 nM. [4]
In vivo	Enalaprilat has unfavourable ionisation characteristics to allow sufficient potency for oral administration, thus Enalaprilat is only suitable for intravenous administration, which is overcome by the esterification with ethanol to produce Enalapril. Administration of Enalaprilat induces a significant reduction of MAP at 70 minutes compared with the placebo group during haemorrhagic shock in rats, and results in a 50% reduction of CO, a general tendency of EB extravasation which is significant in the kidney and lungs, and a significant increase in ileal EB extravasation (53%). [5] Enalaprilat has no effect in nonhypertrophied hearts, but significantly attenuates the greater increase in left ventricular end-diastolic pressure in hypertrophied hearts compared with no drug. [6]
Kinase Assay	Single displacement binding assay: The binding assay is based on the competitive displacement of [125I]351A by Enalaprilat performed on whole endothelial cells. Subconfluent HUVECs in 6-well plates are rinsed with 2 mL binding buffer (140 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl <sub>2</sub> , 1.03 mM MgCl <sub>2</sub> , 0.42 mM NaH <sub>2</sub> PO <sub>4</sub> , 10 mM HEPES, 2 mM sodium pyruvate and 5 mM glucose, pH 7.4), and the culture medium is replaced with 2.5 mL fresh binding buffer containing 5% fetal bovine serum (FBS). The Enalaprilat (2.5-12.5 μL, 0.1-50 nM) or equivalent volumes of diluent are added to the binding buffer. A

## A DRUG SCREENING EXPERT

Kinase Assay	saturating amount of [ <sup>125</sup> I]351A (10 µL, typically 106 cpm) is then added to each sample and the plates are incubated at 37 °C for 2 hours in a thermostatic bath. The cells are then rinsed twice with 1.5 mL binding buffer. Finally, the cells are extracted with 0.5 mL NaOH 1 N, incubated for 5 minutes, and the radioactivity is counted with a gamma counter. The ratio of specific [ <sup>125</sup> I]351A bound to total bound activity (B/B0) is calculated, and the inhibitory potency of Enalaprilat expressed as the concentration of ACE inhibitors able to displace 50% of the bound radioligand, i.e. the IC50.
Cell Research	After 24 hours incubation in serum-free medium (DMEM), cells are stimulated with IGF-I (1-100 nM) and coincubated with Enalaprilat (1 nM-10 µM) for 24 hours. Cellular proliferation is assessed by 5-bromo-2'-deoxyuridine (BrdU) incorporation during the last 4 hours of the 24 hours incubation period using a colorimetric immunoassay. The extinctions are measured at 450 nm in an ELISA plate reader. All values consist of an n=9.(Only for Reference)

### Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 70 mg/mL (200.92 mM),Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.74 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8703 mL	14.3513 mL	28.7026 mL
5 mM	0.5741 mL	2.8703 mL	5.7405 mL
10 mM	0.287 mL	1.4351 mL	2.8703 mL
50 mM	0.0574 mL	0.287 mL	0.5741 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Cecconi C, et al. Eur J Pharmacol, 2007, 577(1-3), 1-6.
- Zou K, et al. J Biol Chem, 2009, 284(46), 31914-31920.
- Stanisavljevic S, et al. J Pharmacol Exp Ther, 2006, 316(3), 1153-1158.
- van Eickels M, et al. Br J Pharmacol, 2000, 131(8), 1592-1596.
- Schumacher J, et al. Br J Anaesth, 2006, 96(4), 437-443.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481